The Value of Metformin in the Treatment of Hidradenitis Suppurativa in a Cohort of Iraqi Patients Swadi Asmaa abdulJaleel1, Jabur Akeel Hamed2 1Lecturer, Ph. D Pharmacology and Therapeutics, Department of Pharmacology, College of Medicine, University of Al-Qadisiyah 2Lecturer, Dermatology Specialist, Department of Medicine, College of Medicine, University of Al-Qadisiyah Online published on 23 December, 2019. Abstract Aim of the study the current cohort study was planned and carried out in order to evaluate the role of newly introduced therapeutic approach, low dose metformin, for hidradenitis suppurativa. This cohort study included 20 patients with hidradenitis suppurativa, 5 males and 15 females. The study was conducted at the dermatology unit, Al-Diwaniyah Teaching Hospital, Al-Diwaniyah Province, Mid-Euphrates Region of Iraq. The study started on November the 2nd 2018 and extended to June the 3rd 2019. Variables included in the current study were age, gender, residency, body mass index (BMI) and other associated illnesses. Outcome in the end of the study included clinical response and main side effects. Following one year of follow up the clinical response was recorded for all patients. Complete response was seen in 8 (40.0%), while, partial response was seen in 12 (60.0%). The only reported sided effect was gastrointestinal upset and was seen in 8 (40.0%). There was no significant association between clinical response and any of the demographic characteristics (P > 0.05). Metformin is a safe an efficient oral therapy for the treatment of hidradenitis suppurativa with negligible side effects. Top Keywords Metformin, hidradenitis suppurativa, Iraq. Top |